Edgewise Therapeutics, Inc. (EWTX): Total Liabilities
$30.35M
As of 2025-12-31
$31.61M
As of 2026-06-30
+14.2%
3-year compound annual growth
+47.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.35M | +9.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $27.60M | +30.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $21.20M | +4.0% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $20.39M | +87.9% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $10.85M | +149.9% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $4.34M | n/a | 2022-02-24, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $30.35M | +9.9% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| Geron Corp (GERN) | 2025-12-31 | $344.67M | +10.0% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $54.87M | +30.6% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $122.11M | -24.0% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $27.78M | +192.2% |
Compare EWTX, LAB, GERN, OLMA side by side · Screen every company in Pharmaceutical Preparations ↗